Roivant Sciences Ltd Asset Resilience Ratio
Roivant Sciences Ltd asset resilience ratio. Roivant Sciences Ltd (ROIV) has an Asset Resilience Ratio of 58.40% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Roivant Sciences Ltd (ROIV) defensive interval to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Roivant Sciences Ltd (2021–2025)
Asset resilience ratio of Roivant Sciences Ltd from 2021 to 2025. This chart shows how Roivant Sciences Ltd's Asset Resilience Ratio has changed over time. Read ROIV total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Roivant Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Roivant Sciences Ltd total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $3.05 Billion | 58.4% |
| Total Liquid Assets | $3.05 Billion | 58.40% |
Asset Resilience Insights
- Very High Liquidity: Roivant Sciences Ltd maintains exceptional liquid asset reserves at 58.40% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Roivant Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Roivant Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Roivant Sciences Ltd Asset Resilience Ratio by Year (2021–2025)
Roivant Sciences Ltd asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for Roivant Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-03-31 | 39.94% | $2.17 Billion | $5.44 Billion | +39.87pp |
| 2024-03-31 | 0.07% | $5.37 Million | $7.22 Billion | -0.14pp |
| 2023-03-31 | 0.21% | $5.01 Million | $2.39 Billion | -0.32pp |
| 2022-03-31 | 0.53% | $13.63 Million | $2.59 Billion | -2.36pp |
| 2021-03-31 | 2.89% | $77.70 Million | $2.69 Billion | -- |
About Roivant Sciences Ltd
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody that targets the neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease… Read more